The metal-based drugs represented by cisplatin, carboplatin, and oxaliplatin, prevail in cancer treatment, whereas new therapeutics are extremely slow to step into the clinic. Poor pharmacokinetics, multidrug resistance, and severe side effects greatly limit the development of metal-based anticancer drugs. The robustness and modular composition of supramolecular coordination complexes allow for the incorporation of novel diagnostic and therapeutic modalities, showing promising potentials for precise cancer theranostics. In this mini review, we highlight the recent advances in the development of supramolecular coordination complexes as diagnostic and therapeutic agents. The key focuses of these reports lie in searching sophisticated coordination ligands and nanoformulations that can potentially solve the issues faced by current metal-based drugs including imaging, resistance, toxicity, and pharmacological deficiencies.

以顺铂、卡铂和奥沙利铂为代表的金属类药物在癌症治疗中占主导地位，而新疗法进入临床的速度极慢。药代动力学差、多药耐药和严重的副作用极大地限制了金属基抗癌药物的开发。超分子配位复合物的稳健性和模块化组成允许结合新的诊断和治疗方式，显示出用于精确癌症治疗学的有希望的潜力。在这篇小型综述中，我们重点介绍了超分子配位配合物作为诊断和治疗剂的最新进展。